- Report
- August 2024
- 100 Pages
Global
From €5430EUR$5,950USD£4,630GBP
- Report
- July 2024
- 200 Pages
Global
From €4517EUR$4,949USD£3,851GBP
- Report
- February 2024
- 112 Pages
Global
From €4335EUR$4,750USD£3,696GBP
- Drug Pipelines
- April 2023
- 117 Pages
Global
From €13685EUR$14,995USD£11,669GBP
- Report
- December 2019
- 356 Pages
Global
From €13685EUR$14,995USD£11,669GBP
- Report
- July 2018
- 765 Pages
Global
From €20078EUR$22,000USD£17,120GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €456EUR$500USD£389GBP
- Report
- March 2025
- 97 Pages
Global
From €3500EUR$4,108USD£3,089GBP
Tecfidera is a medication used to treat relapsing forms of multiple sclerosis (MS). It is a disease-modifying drug (DMD) that works by reducing the frequency and severity of MS relapses. Tecfidera is an oral medication that is taken twice daily. It is a dimethyl fumarate, which is thought to reduce inflammation in the central nervous system. It is also thought to reduce the number of white blood cells that attack the myelin sheath, which is the protective coating around nerve cells.
Tecfidera is one of several DMDs used to treat MS. Other DMDs include interferon beta, glatiramer acetate, and natalizumab. These medications are used to reduce the frequency and severity of MS relapses, as well as to slow the progression of the disease.
The market for Tecfidera includes companies such as Biogen, Merck, and Novartis. These companies manufacture and distribute the medication, as well as provide support services for patients taking the medication. Show Less Read more